Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990;100(1):115-8.
doi: 10.1007/BF02245800.

Evidence for 5-HT2 receptor mediation in quipazine anorexia

Affiliations

Evidence for 5-HT2 receptor mediation in quipazine anorexia

R Shukla et al. Psychopharmacology (Berl). 1990.

Abstract

Doses of d-amphetamine (3.2 mg/kg), fenfluramine (10 mg/kg) and quipazine (8 mg/kg) cause a significant reduction in food intake during a 30-min daily feeding session in food-deprived rats. Pirenperone and ritanserin, 5-HT2 receptor antagonists, significantly blocked the anorectic effect of quipazine, while d-amphetamine and fenfluramine effects were not modified. Metergoline, a non-specific blocker of 5-HT receptors, significantly blocked the anorectic effects of fenfluramine and quipazine, but not the d-amphetamine effect. Pretreatment with alpha- and beta-adrenergic receptor antagonists (prazosin, propranolol and pindolol), dopamine receptor antagonists (haloperidol and pimozide), the catecholamine synthesis inhibitor alpha-methyl-para-tyrosine, and the opioid receptor antagonist naloxone failed to modify the anorectic effects of all three agents, with the exception that quipazine-induced anorexia was significantly reduced by pimozide. These results suggest that the quipazine anorexia is largely mediating through 5-HT2 receptors, although the effect of pimozide remains to be explained. Consistent with previous studies, the fenfluramine effect appears to be mediated through 5-HT1B receptors. Receptors involved in the anorectic effect of higher doses of d-amphetamine are still unidentified by this analysis. Further investigation is required to define the mechanisms by which quipazine and larger doses of d-amphetamine bring about a reduced appetite for food.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Eur J Pharmacol. 1988 Jan 12;145(2):227-30 - PubMed
    1. Clin Neuropharmacol. 1988;11 Suppl 1:S8-32 - PubMed
    1. Eur J Pharmacol. 1983 Jul 22;91(2-3):189-96 - PubMed
    1. Brain Res Bull. 1986 Nov;17(5):681-9 - PubMed
    1. Commun Psychopharmacol. 1977;1(6):525-31 - PubMed

Publication types

LinkOut - more resources